Amendments to the Claims:

The following Listing of Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-21 (canceled)

22. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (I):



(I)

wherein: X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

Z is –S-, -SO-, or-SO_2-;

R_1 is selected from the group consisting of:

-alkyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkenyl;

-R_4–aryl;

-R_4–heteroaryl;

-R_4–heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

$-N(R_3)_2$;

$-CO-N(R_3)_2$;

$-CO-C_{1-10}$ alkyl;

$-CO-O-C_{1-10}$ alkyl;

$-N_3$;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or C_{1-10} alkyl;

R_4 is alkyl or alkenyl;

Y is –O– or $-S(O)_{0-2}-$;

n is 0 to 4; and

each R present is independently selected from the group consisting of C_{1-10} alkyl, C_{1-10} alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

23-25 (canceled)

26. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound selected from the group consisting of:

2-butyl-1-[4-(phenylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[2-(phenylthio)ethyl]-6,7,8,9-tetrahydro-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[4-(phenylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[4-(methylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[4-(methylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[2-(phenylthio)ethyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[4-(phenylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[4-(methylsulfonyl)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[4-(phenylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[4-(methylthio)butyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-methyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-ethyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-hexyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-(2-methoxyethyl)-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[5-(methylthio)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[5-(methylsulfinyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

2-butyl-1-[3-(methylsulfonyl)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine; and

2-butyl-1-[3-(phenylsulfonyl)propyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

27-30 (canceled)

31. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of the formula (II):



(II)

wherein: X is $-CHR_3-$, $-CHR_3$-alkyl-, or $-CHR_3$-alkenyl-;

Z is –S-, -SO-, or $-SO_2-$;

R_1 is selected from the group consisting of:

-alkyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkenyl;

$-R_4$–aryl;

$-R_4$–heteroaryl; and

$-R_4$–heterocyclyl;

R_2 is selected from the group consisting of:

-hydrogen;

-alkyl;

-alkenyl;

-aryl;

-heteroaryl;

-heterocyclyl;

-alkyl-Y-alkyl;

-alkyl-Y-alkenyl;

-alkyl-Y-aryl; and

-alkyl or alkenyl substituted by one or more substituents selected from the group consisting of:

-OH;

-halogen;

-$N(R_3)_2$;

-$CO\text{-}N(R_3)_2$;

-$CO\text{-}C_{1\text{-}10}$ alkyl;

-$CO\text{-}O\text{-}C_{1\text{-}10}$ alkyl;

-N_3;

-aryl;

-heteroaryl;

-heterocyclyl;

-CO-aryl; and

-CO-heteroaryl;

each R_3 is independently H or $C_{1\text{-}10}$ alkyl;

R_4 is alkyl or alkenyl;

Y is –O– or $–S(O)_{0\text{-}2}$-;

n is 0 to 4; and

each R present is independently selected from the group consisting of $C_{1\text{-}10}$ alkyl, $C_{1\text{-}10}$ alkoxy, hydroxy, halogen and trifluoromethyl;

or a pharmaceutically acceptable salt thereof, that induces cytokine biosynthesis.

32. (previously presented) The compound 2-butyl-1-[5-(methylsulfonyl)pentyl]-1*H*-imidazo[4,5-*c*]quinolin-4-amine or a pharmaceutically acceptable salt thereof.

33-34 (canceled)

35. (previously presented) A method of treating a neoplastic disease in an animal in need thereof comprising administering to the animal a therapeutically effective amount of a compound of claim 32 that induces cytokine biosynthesis.